S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NYSE:ABC

AmerisourceBergen Competitors

$101.22
-1.63 (-1.58 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$100.71
Now: $101.22
$103.40
50-Day Range
$102.85
MA: $106.52
$111.92
52-Week Range
$72.06
Now: $101.22
$112.88
Volume1.33 million shs
Average Volume1.32 million shs
Market Capitalization$20.72 billion
P/E RatioN/A
Dividend Yield1.71%
Beta0.57

Competitors

AmerisourceBergen (NYSE:ABC) Vs. GILD, ANTM, ZTS, BDX, ILMN, and MRNA

Should you be buying ABC stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to AmerisourceBergen, including Gilead Sciences (GILD), Anthem (ANTM), Zoetis (ZTS), Becton, Dickinson and (BDX), Illumina (ILMN), and Moderna (MRNA).

Gilead Sciences (NASDAQ:GILD) and AmerisourceBergen (NYSE:ABC) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Gilead Sciences and AmerisourceBergen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences1121202.44
AmerisourceBergen03702.70

Gilead Sciences currently has a consensus target price of $96.0370, indicating a potential upside of 56.41%. AmerisourceBergen has a consensus target price of $121.1111, indicating a potential upside of 19.65%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than AmerisourceBergen.

Valuation & Earnings

This table compares Gilead Sciences and AmerisourceBergen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.43$5.39 billion$6.1410.00
AmerisourceBergen$189.89 billion0.11$-3,408,720,000.00$7.9012.81

Gilead Sciences has higher earnings, but lower revenue than AmerisourceBergen. Gilead Sciences is trading at a lower price-to-earnings ratio than AmerisourceBergen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, AmerisourceBergen has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and AmerisourceBergen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
AmerisourceBergen-1.80%65.93%3.91%

Insider & Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 63.4% of AmerisourceBergen shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 28.3% of AmerisourceBergen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

Gilead Sciences pays an annual dividend of $2.72 per share and has a dividend yield of 4.4%. AmerisourceBergen pays an annual dividend of $1.76 per share and has a dividend yield of 1.7%. Gilead Sciences pays out 44.3% of its earnings in the form of a dividend. AmerisourceBergen pays out 22.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has raised its dividend for 1 consecutive years and AmerisourceBergen has raised its dividend for 1 consecutive years.

Summary

Gilead Sciences beats AmerisourceBergen on 9 of the 16 factors compared between the two stocks.

Anthem (NYSE:ANTM) and AmerisourceBergen (NYSE:ABC) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Anthem and AmerisourceBergen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anthem031402.82
AmerisourceBergen03702.70

Anthem currently has a consensus target price of $357.2105, indicating a potential upside of 17.82%. AmerisourceBergen has a consensus target price of $121.1111, indicating a potential upside of 19.65%. Given AmerisourceBergen's higher probable upside, analysts plainly believe AmerisourceBergen is more favorable than Anthem.

Valuation & Earnings

This table compares Anthem and AmerisourceBergen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anthem$104.21 billion0.71$4.81 billion$19.4415.60
AmerisourceBergen$189.89 billion0.11$-3,408,720,000.00$7.9012.81

Anthem has higher earnings, but lower revenue than AmerisourceBergen. AmerisourceBergen is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Anthem has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, AmerisourceBergen has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Profitability

This table compares Anthem and AmerisourceBergen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anthem4.22%18.45%7.27%
AmerisourceBergen-1.80%65.93%3.91%

Insider & Institutional Ownership

89.4% of Anthem shares are held by institutional investors. Comparatively, 63.4% of AmerisourceBergen shares are held by institutional investors. 0.2% of Anthem shares are held by company insiders. Comparatively, 28.3% of AmerisourceBergen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dividends

Anthem pays an annual dividend of $3.80 per share and has a dividend yield of 1.3%. AmerisourceBergen pays an annual dividend of $1.76 per share and has a dividend yield of 1.7%. Anthem pays out 19.5% of its earnings in the form of a dividend. AmerisourceBergen pays out 22.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Anthem has raised its dividend for 1 consecutive years and AmerisourceBergen has raised its dividend for 1 consecutive years.

Summary

Anthem beats AmerisourceBergen on 11 of the 16 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and AmerisourceBergen (NYSE:ABC) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Insider & Institutional Ownership

92.5% of Zoetis shares are held by institutional investors. Comparatively, 63.4% of AmerisourceBergen shares are held by institutional investors. 0.2% of Zoetis shares are held by company insiders. Comparatively, 28.3% of AmerisourceBergen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Zoetis and AmerisourceBergen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.26 billion11.78$1.50 billion$3.6442.65
AmerisourceBergen$189.89 billion0.11$-3,408,720,000.00$7.9012.81

Zoetis has higher earnings, but lower revenue than AmerisourceBergen. AmerisourceBergen is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Zoetis and AmerisourceBergen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis07802.53
AmerisourceBergen03702.70

Zoetis currently has a consensus target price of $167.25, indicating a potential upside of 7.74%. AmerisourceBergen has a consensus target price of $121.1111, indicating a potential upside of 19.65%. Given AmerisourceBergen's stronger consensus rating and higher probable upside, analysts plainly believe AmerisourceBergen is more favorable than Zoetis.

Volatility and Risk

Zoetis has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, AmerisourceBergen has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.6%. AmerisourceBergen pays an annual dividend of $1.76 per share and has a dividend yield of 1.7%. Zoetis pays out 27.5% of its earnings in the form of a dividend. AmerisourceBergen pays out 22.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and AmerisourceBergen has raised its dividend for 1 consecutive years. AmerisourceBergen is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Zoetis and AmerisourceBergen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.50%63.89%14.99%
AmerisourceBergen-1.80%65.93%3.91%

Becton, Dickinson and (NYSE:BDX) and AmerisourceBergen (NYSE:ABC) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Insider & Institutional Ownership

83.2% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 63.4% of AmerisourceBergen shares are owned by institutional investors. 0.8% of Becton, Dickinson and shares are owned by insiders. Comparatively, 28.3% of AmerisourceBergen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Becton, Dickinson and and AmerisourceBergen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and$17.12 billion4.09$874 million$10.2023.64
AmerisourceBergen$189.89 billion0.11$-3,408,720,000.00$7.9012.81

Becton, Dickinson and has higher earnings, but lower revenue than AmerisourceBergen. AmerisourceBergen is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Becton, Dickinson and and AmerisourceBergen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Becton, Dickinson and06702.54
AmerisourceBergen03702.70

Becton, Dickinson and currently has a consensus price target of $281.5455, indicating a potential upside of 16.75%. AmerisourceBergen has a consensus price target of $121.1111, indicating a potential upside of 19.65%. Given AmerisourceBergen's stronger consensus rating and higher probable upside, analysts clearly believe AmerisourceBergen is more favorable than Becton, Dickinson and.

Risk & Volatility

Becton, Dickinson and has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, AmerisourceBergen has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.

Dividends

Becton, Dickinson and pays an annual dividend of $3.32 per share and has a dividend yield of 1.4%. AmerisourceBergen pays an annual dividend of $1.76 per share and has a dividend yield of 1.7%. Becton, Dickinson and pays out 32.5% of its earnings in the form of a dividend. AmerisourceBergen pays out 22.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Becton, Dickinson and has increased its dividend for 50 consecutive years and AmerisourceBergen has increased its dividend for 1 consecutive years. AmerisourceBergen is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Becton, Dickinson and and AmerisourceBergen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Becton, Dickinson and5.11%13.30%5.60%
AmerisourceBergen-1.80%65.93%3.91%

Summary

Becton, Dickinson and beats AmerisourceBergen on 9 of the 16 factors compared between the two stocks.

Illumina (NASDAQ:ILMN) and AmerisourceBergen (NYSE:ABC) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Illumina and AmerisourceBergen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Illumina38702.22
AmerisourceBergen03702.70

Illumina currently has a consensus price target of $365.3158, indicating a potential downside of 16.86%. AmerisourceBergen has a consensus price target of $121.1111, indicating a potential upside of 19.65%. Given AmerisourceBergen's stronger consensus rating and higher probable upside, analysts clearly believe AmerisourceBergen is more favorable than Illumina.

Institutional & Insider Ownership

90.0% of Illumina shares are held by institutional investors. Comparatively, 63.4% of AmerisourceBergen shares are held by institutional investors. 0.4% of Illumina shares are held by company insiders. Comparatively, 28.3% of AmerisourceBergen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Illumina and AmerisourceBergen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Illumina19.70%15.93%10.09%
AmerisourceBergen-1.80%65.93%3.91%

Volatility & Risk

Illumina has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, AmerisourceBergen has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.

Valuation & Earnings

This table compares Illumina and AmerisourceBergen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$3.54 billion18.09$1.00 billion$6.5766.88
AmerisourceBergen$189.89 billion0.11$-3,408,720,000.00$7.9012.81

Illumina has higher earnings, but lower revenue than AmerisourceBergen. AmerisourceBergen is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats AmerisourceBergen on 7 of the 13 factors compared between the two stocks.

AmerisourceBergen (NYSE:ABC) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for AmerisourceBergen and Moderna, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AmerisourceBergen03702.70
Moderna36902.33

AmerisourceBergen currently has a consensus price target of $121.1111, indicating a potential upside of 19.65%. Moderna has a consensus price target of $145.2353, indicating a potential downside of 6.18%. Given AmerisourceBergen's stronger consensus rating and higher probable upside, analysts clearly believe AmerisourceBergen is more favorable than Moderna.

Institutional & Insider Ownership

63.4% of AmerisourceBergen shares are held by institutional investors. Comparatively, 51.2% of Moderna shares are held by institutional investors. 28.3% of AmerisourceBergen shares are held by insiders. Comparatively, 29.2% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares AmerisourceBergen and Moderna's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AmerisourceBergen-1.80%65.93%3.91%
Moderna-242.73%-28.11%-20.31%

Volatility and Risk

AmerisourceBergen has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.

Earnings & Valuation

This table compares AmerisourceBergen and Moderna's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AmerisourceBergen$189.89 billion0.11$-3,408,720,000.00$7.9012.81
Moderna$60.21 million1,017.44$-514,020,000.00($1.55)-99.88

Moderna has lower revenue, but higher earnings than AmerisourceBergen. Moderna is trading at a lower price-to-earnings ratio than AmerisourceBergen, indicating that it is currently the more affordable of the two stocks.

Summary

AmerisourceBergen beats Moderna on 9 of the 14 factors compared between the two stocks.


AmerisourceBergen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Gilead Sciences logo
GILD
Gilead Sciences
2.8$61.40-2.3%$76.97 billion$22.45 billion63.30Gap Down
Anthem logo
ANTM
Anthem
2.6$303.19-1.0%$74.25 billion$104.21 billion15.68
Zoetis logo
ZTS
Zoetis
2.1$155.24-0.8%$73.76 billion$6.26 billion46.07Insider Buying
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.4$241.15-2.5%$70.07 billion$17.12 billion88.33Gap Down
Illumina logo
ILMN
Illumina
1.7$439.41-1.5%$64.11 billion$3.54 billion101.95
Moderna logo
MRNA
Moderna
1.6$154.81-4.2%$61.26 billion$60.21 million-95.56Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
Analyst Revision
News Coverage
Gap Down
HCA Healthcare logo
HCA
HCA Healthcare
2.5$172.03-1.7%$58.48 billion$51.34 billion17.39Insider Selling
Increase in Short Interest
Boston Scientific logo
BSX
Boston Scientific
2.2$38.78-2.3%$55.53 billion$10.74 billion14.86Insider Selling
Increase in Short Interest
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$212.55-0.2%$55.25 billion$4.16 billion26.84Analyst Upgrade
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
2.0$16.71-0.2%$52.68 billion$30.20 billion55.70News Coverage
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$83.10-1.0%$51.90 billion$4.35 billion66.48Insider Selling
Increase in Short Interest
Humana logo
HUM
Humana
2.3$379.65-0.2%$48.92 billion$64.89 billion12.17Insider Selling
Decrease in Short Interest
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$450.57-0.6%$48.27 billion$7.86 billion16.47Analyst Report
News Coverage
Align Technology logo
ALGN
Align Technology
2.0$567.11-1.9%$44.72 billion$2.41 billion25.80Insider Selling
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$520.17-0.4%$44.44 billion$2.41 billion90.62Insider Selling
Biogen logo
BIIB
Biogen
2.1$272.88-1.6%$41.57 billion$14.38 billion9.03
Baxter International logo
BAX
Baxter International
2.3$77.69-1.2%$39.24 billion$11.36 billion44.14
DexCom logo
DXCM
DexCom
1.7$397.78-0.6%$38.26 billion$1.48 billion164.37Insider Selling
Centene logo
CNC
Centene
2.1$58.54-0.4%$34.05 billion$74.64 billion16.31
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.1$163.06-0.9%$33.89 billion$7.98 billion1,019.19
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$152.75-0.6%$33.58 billion$4.99 billion35.69Increase in Short Interest
Alcon logo
ALC
Alcon
1.2$68.40-2.3%$33.39 billion$7.51 billion-46.53Earnings Announcement
Analyst Downgrade
Decrease in Short Interest
Analyst Revision
Gap Down
Teladoc Health logo
TDOC
Teladoc Health
1.5$221.09-0.7%$32.05 billion$553.31 million-154.61Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
BeiGene logo
BGNE
BeiGene
1.1$320.00-3.0%$29.27 billion$428.21 million-15.83Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
ResMed logo
RMD
ResMed
1.4$192.78-1.1%$28.05 billion$2.96 billion41.37News Coverage
Seagen logo
SGEN
Seagen
1.5$151.11-0.7%$27.38 billion$916.71 million59.49Decrease in Short Interest
McKesson logo
MCK
McKesson
2.4$169.52-2.7%$26.98 billion$231.05 billion12.90Gap Down
BioNTech logo
BNTX
BioNTech
0.9$109.03-3.0%$26.25 billion$121.63 million-54.52Decrease in Short Interest
News Coverage
Gap Down
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.6$239.91-1.4%$23.37 billion$11.55 billion27.93
Exact Sciences logo
EXAS
Exact Sciences
1.6$136.12-3.5%$23.02 billion$876.29 million-61.59Analyst Downgrade
Insider Selling
News Coverage
Gap Up
Genmab A/S logo
GMAB
Genmab A/S
1.5$33.87-0.6%$22.20 billion$804.57 million26.26Earnings Announcement
Analyst Upgrade
Increase in Short Interest
Analyst Revision
News Coverage
Gap Down
Cerner logo
CERN
Cerner
2.9$69.14-1.2%$21.18 billion$5.69 billion27.01Insider Buying
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
2.1$280.65-1.1%$20.80 billion$1.84 billion74.05Dividend Announcement
Analyst Upgrade
Decrease in Short Interest
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.9$34.50-1.5%$20.21 billion$19.58 billion13.69Analyst Downgrade
Increase in Short Interest
Analyst Revision
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$90.91-0.4%$20.06 billion$1.30 billion24.84Earnings Announcement
Insider Selling
Catalent logo
CTLT
Catalent
1.5$113.71-1.3%$19.36 billion$3.09 billion72.43
The Cooper Companies logo
COO
The Cooper Companies
1.7$386.13-1.6%$18.98 billion$2.43 billion80.28Upcoming Earnings
Analyst Report
Gap Down
Hologic logo
HOLX
Hologic
2.1$72.09-0.4%$18.57 billion$3.78 billion17.16
Teleflex logo
TFX
Teleflex
2.0$398.12-1.1%$18.54 billion$2.60 billion51.24Earnings Announcement
Dividend Announcement
Analyst Report
Analyst Revision
BIO.B
Bio-Rad Laboratories
0.7$600.70-0.0%$17.92 billion$2.31 billion5.14
10x Genomics logo
TXG
10x Genomics
1.6$177.99-2.7%$17.86 billion$245.89 million-131.84Analyst Downgrade
News Coverage
CureVac logo
CVAC
CureVac
0.6$94.30-1.4%$17.63 billionN/A0.00Decrease in Short Interest
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$584.50-0.4%$17.44 billion$2.31 billion5.00
GDRX
GoodRx
1.2$44.52-2.3%$17.38 billion$388.22 million0.00
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$148.10-1.0%$17.33 billion$219.75 million-18.91
Incyte logo
INCY
Incyte
1.9$78.66-0.3%$17.29 billion$2.16 billion-50.10Insider Buying
Insulet logo
PODD
Insulet
1.3$259.10-1.4%$17.08 billion$738.20 million588.88Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Smith & Nephew logo
SNN
Smith & Nephew
2.0$38.85-2.0%$17.04 billion$5.14 billion19.04Dividend Increase
Analyst Report
High Trading Volume
News Coverage
Avantor logo
AVTR
Avantor
1.8$27.87-0.8%$16.19 billion$6.04 billion232.25Insider Selling
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$175.27-0.3%$16.10 billion$3.17 billion59.82Analyst Downgrade
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.